Identification
- Generic Name
- Alkaline Phosphatase
- DrugBank Accession Number
- DB05768
- Background
Alkaline Phosphatase (AP) is an oral treatment and has a very favorable side-effect profile. AP only acts locally in the colon to reduce the continuous inflammation of the colon by endotoxin from Gram-negative bacteria and extracellular ATP in UC patients.
- Type
- Small Molecule
- Groups
- Investigational
- Synonyms
- Not Available
Pharmacology
- Indication
Investigated for use/treatment in ulcerative colitis.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Patients with UC have reduced AP levels and activity in the inflamed tissue in the intestines. A short treatment with AP helps to restore the intestinal mucosal barrier in UC patients, which can be classified as a disease modifying antiinflammatory effect.
- Mechanism of action
Two substrates that can disturb the homeostasis in human organs are endotoxin from Gram-negative bacteria (LPS) and adenosine triphosphate (ATP). Dephosphorylation of LPS and extracellular ATP by AP has been shown to result in restoration of homeostasis in the target organs such as GI tract and kidney, through reduction of inflammationinduced damage. In the gastrointestinal tract, the prime source of LPS is derived from the residing Gram-negative microorganisms. In UC patients the mucosal surface of the colon wall is characterized by intermittent lesions and hyperpermeability caused by chronic inflammation. A consequence of the damaged intestinal mucosa is a reduced AP level and an increased influx of LPS responsive cells that maintain the inflammatory response. In the gastrointestinal tract, the prime source of LPS is derived from the residing Gram-negative microorganisms. AP reduces LPS-mediated inflammation, by preventing activation of the intestinal epithelium and preventing systemic inflammatory responses that result from transmigration of endotoxin though the leaky inflamed intestinal mucosa.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347910221
- Wikipedia
- Alkaline_phosphatase
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Recruiting Treatment Acute Kidney Injury Due to Sepsis (Disorder) / Coronavirus Disease 2019 (COVID‑19) 1 2 Completed Treatment Acute Kidney Injury (AKI) 1 2 Completed Treatment Hypophosphatasia (HPP) 2 2 Completed Treatment Organ Dysfunction Syndrome, Multiple / Sepsis 1 2 Completed Treatment Sepsis / Severe / Shock 1 2 Completed Treatment Ulcerative Colitis 1 2 Withdrawn Treatment Hypophosphatasia (HPP) 1 1 Completed Treatment Enteritis Caused by Radiation (Disorder) 1 1, 2 Completed Treatment Acute Rheumatoid Arthritis 1 1, 2 Completed Treatment Hypophosphatasia (HPP) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at November 18, 2007 18:27 / Updated at June 12, 2020 16:52